- Home
- GILD vs SPGI Comparison
GILD vs SPGI Comparison
Compare GILD & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- SPGI
- Stock Information
- Founded
- GILD 1987
- SPGI 1860
- Country
- GILD United States
- SPGI United States
- Employees
- GILD N/A
- SPGI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- SPGI Finance: Consumer Services
- Sector
- GILD Health Care
- SPGI Finance
- Exchange
- GILD Nasdaq
- SPGI Nasdaq
- Market Cap
- GILD 133.3B
- SPGI 158.5B
- IPO Year
- GILD 1992
- SPGI N/A
- Fundamental
- Price
- GILD $111.73
- SPGI $529.37
- Analyst Decision
- GILD Buy
- SPGI Strong Buy
- Analyst Count
- GILD 25
- SPGI 15
- Target Price
- GILD $110.17
- SPGI $588.43
- AVG Volume (30 Days)
- GILD 8.9M
- SPGI 1.2M
- Earning Date
- GILD 08-07-2025
- SPGI 07-31-2025
- Dividend Yield
- GILD 2.83%
- SPGI 0.73%
- EPS Growth
- GILD 1118.07
- SPGI 42.93
- EPS
- GILD 4.73
- SPGI 12.73
- Revenue
- GILD $28,735,000,000.00
- SPGI $14,494,000,000.00
- Revenue This Year
- GILD $1.59
- SPGI $7.17
- Revenue Next Year
- GILD $3.67
- SPGI $7.15
- P/E Ratio
- GILD $23.62
- SPGI $41.58
- Revenue Growth
- GILD 4.68
- SPGI 12.99
- 52 Week Low
- GILD $66.01
- SPGI $427.14
- 52 Week High
- GILD $119.96
- SPGI $545.39
- Technical
- Relative Strength Index (RSI)
- GILD 58.05
- SPGI 59.95
- Support Level
- GILD $104.46
- SPGI $513.63
- Resistance Level
- GILD $112.00
- SPGI $528.16
- Average True Range (ATR)
- GILD 2.78
- SPGI 7.65
- MACD
- GILD 0.05
- SPGI 1.36
- Stochastic Oscillator
- GILD 89.70
- SPGI 88.30
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.